# Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

> **NCT00350948** · PHASE3 · TERMINATED · sponsor: **Telik** · enrollment: 244 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Telcyta
- **DRUG:** Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT00350948
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 244 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2013-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350948, "Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00350948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*